Drug intelligence / Profile preview

S-268023

Development stage: Unknown
Lead developer: Shionogi
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

S-268023 is a recombinant protein subunit vaccine candidate developed by Shionogi & Co., Ltd., specifically designed to target the SARS-CoV-2 Omicron BA.1 variant. The vaccine consists of a purified, stabilized version of the viral spike protein produced using a baculovirus expression system in insect cells. It is intended for use as a booster dose to provide enhanced protection against the Omicron variant, which exhibits significant mutations in the spike protein compared to the ancestral strain. Clinical development reached Phase 3, where its immunogenicity and safety were evaluated in comparison to existing mRNA-based booster vaccines.

Other names: Omicron BA.1-adapted COVID-19 vaccineShionogi Omicron vaccine

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on S-268023.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S-268023.

Explore the full profile